Acesso livre
Acesso livre

Infectologia

[Comunicado de imprensa – ainda não publicado] Estudo laboratorial sugere que uma terceira dose (reforço) da vacina da Pfizer–BioNTech pode ser necessária para fornecer uma resposta imunológica adequada à variante Ômicron.

9 Dez, 2021 | 15:35h

Comunicado de imprensa: Pfizer and Biontech provide update on Omicron variant

Comentários:

Omicron likely to weaken COVID vaccine protection – Nature

Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP

Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre

Covid: Pfizer says booster shot promising against Omicron – BBC

Pfizer-BioNTech Covid-19 shot loses power against Omicron variant, but booster restores protection – STAT

Enquanto 57 países relatam casos relacionados à Ômicron, Pfizer afirma que suas doses de reforço oferecem proteção – mas OMS alerta que mais pesquisas são necessárias.

9 Dez, 2021 | 15:33h

As 57 Countries Report Omicron Cases, Pfizer Says its Boosters Offer Protection – But WHO Cautions More Research is Needed – Health Policy Watch

Ver também: Covid: Vaccines should work against Omicron variant, WHO says – BBC

Múltiplos estudos preliminares encontram evasão notável da Ômicron à vacina.

9 Dez, 2021 | 15:32h

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

Conteúdo relacionado: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

Opinião | Por que ainda isolamos pessoas vacinadas por 10 dias?

9 Dez, 2021 | 15:31h

Why Are We Still Isolating Vaccinated People for 10 Days? – The Atlantic

Tratamento moderno da efusão pleural unilateral.

9 Dez, 2021 | 15:16h

Modern day management of a unilateral pleural effusion – Clinical Medicine Journal

OMS faz recomendação contra o uso de plasma convalescente para tratar COVID-19.

8 Dez, 2021 | 13:22h

Comunicado de imprensa: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization

Ver orientação: WHO’s living guidelines on COVID-19 therapeutics

Infográfico: A living WHO guideline on drugs for covid-19 – The BMJ

 

Comentário no Twitter (fio – clique para saber mais)

 

Um primeiro e pequeno estudo sugere que a variante Ômicron é uma ameaça maior à imunidade contra Covid-19 do que outras variantes.

8 Dez, 2021 | 13:20h

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Estudo original: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

 

Comentário do autor no Twitter (fio – clique para saber mais)

Ver também (fio – clique para saber mais)

 

[Preprint] Risco de internação, doença grave e mortalidade por COVID-19 em crianças infectadas pelo SARS-CoV-2 na Alemanha – “A taxa de internação geral associada com infecção por SARS-CoV-2 foi de 35,9 por 10.000 crianças; a taxa de admissão em UTI foi de 1,7 por 10.000 e a taxa de casos fatais foi de 0,09 por 10.000.”

8 Dez, 2021 | 13:18h

Risk of Hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany – medRxiv

Conteúdos relacionados:

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

Review: Should children under 12 years of age be vaccinated against COVID-19?

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

Estudo randomizado | Em pacientes com Covid-19 grave, o cateter nasal de alto fluxo reduziu a chance de ventilação mecânica invasiva e diminuiu o tempo de recuperação clínica, em comparação à oxigenoterapia convencional.

8 Dez, 2021 | 13:16h

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial – JAMA

Conteúdos relacionados:

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

Estudo randomizado de fase 2 | Imunogenicidade e segurança da terceira dose da CoronaVac e persistência imune de esquema de 2 doses.

8 Dez, 2021 | 13:15h

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases

Comentário convidado: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.